» Articles » PMID: 22678056

Amyloid Precursor Protein (APP) Contributes to Pathology in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis

Overview
Journal Hum Mol Genet
Date 2012 Jun 9
PMID 22678056
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

In amyotrophic lateral sclerosis (ALS), the progressive loss of motor neurons is accompanied by extensive muscle denervation, resulting in paralysis and ultimately death. Upregulation of amyloid beta (A4) precursor protein (APP) in muscle fibres coincides with symptom onset in both sporadic ALS patients and the SOD1(G93A) mouse model of familial ALS. We have further characterized this response in SOD1(G93A) mice and also revealed elevated levels of β-amyloid (Aβ) peptides in the SOD1(G93A) spinal cord, which were predominantly localized within motor neurons and their surrounding glial cells. We therefore examined the effect of genetic ablation of APP on disease progression in SOD1(G93A) mice, which significantly improved multiple disease parameters, including innervation, motor function, muscle contractile characteristics, motor unit and motor neuron survival. These results therefore strongly suggest that APP actively contributes to SOD1(G93A)-mediated pathology. Together with observations from ALS cases, this study indicates that APP may contribute to human ALS pathology.

Citing Articles

Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.

Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X Signal Transduct Target Ther. 2025; 10(1):31.

PMID: 39894843 PMC: 11788444. DOI: 10.1038/s41392-024-02071-0.


Proteomic analysis of cerebrospinal fluid of amyotrophic lateral sclerosis patients in the presence of autologous bone marrow derived mesenchymal stem cells.

Reis A, Maximino J, Lage L, Gomes H, Pereira J, Brofman P Stem Cell Res Ther. 2024; 15(1):301.

PMID: 39278909 PMC: 11403799. DOI: 10.1186/s13287-024-03820-2.


Protein Biomarkers Shared by Multiple Neurodegenerative Diseases Are Calmodulin-Binding Proteins Offering Novel and Potentially Universal Therapeutic Targets.

ODay D J Clin Med. 2023; 12(22).

PMID: 38002659 PMC: 10672630. DOI: 10.3390/jcm12227045.


Skeletal muscle as a molecular and cellular biomarker of disease progression in amyotrophic lateral sclerosis: a narrative review.

King P Neural Regen Res. 2023; 19(4):747-753.

PMID: 37843208 PMC: 10664124. DOI: 10.4103/1673-5374.382226.


Differential Expression of MicroRNAs and Predicted Drug Target in Amyotrophic Lateral Sclerosis.

Ben Patel R, Bajpai A, Thirumurugan K J Mol Neurosci. 2023; 73(6):375-390.

PMID: 37249795 DOI: 10.1007/s12031-023-02124-z.